Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
5.98
+0.06 (1.01%)
At close: Dec 5, 2025, 4:00 PM EST
5.96
-0.02 (-0.33%)
After-hours: Dec 5, 2025, 7:36 PM EST
Ardelyx Employees
Ardelyx had 395 employees as of December 31, 2024. The number of employees increased by 128 or 47.94% compared to the previous year.
Employees
395
Change (1Y)
128
Growth (1Y)
47.94%
Revenue / Employee
$1,008,187
Profits / Employee
-$143,157
Market Cap
1.45B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARDX News
- 4 weeks ago - Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week - GlobeNewsWire
- 4 weeks ago - Ardelyx to Participate at the Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 4 weeks ago - Ardelyx: Impressive Q3 Record Growth - Why I Buy - Seeking Alpha
- 4 weeks ago - Ardelyx: A Long Overdue Rally - Seeking Alpha
- 4 weeks ago - Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference - GlobeNewsWire
- 5 weeks ago - Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology's 2025 Annual Meeting - GlobeNewsWire